Evropska unija - slovenščina - EMA (European Medicines Agency)

novo nordisk a/s - insulin human - sladkorna bolezen - zdravila, ki se uporabljajo pri diabetesu - zdravljenje diabetes mellitus.

Evropska unija - slovenščina - EMA (European Medicines Agency)

janssen-cilag international nv - canagliflozin, metformin hidroklorid - diabetes mellitus, tip 2 - zdravila, ki se uporabljajo pri diabetesu - vokanamet je navedeno pri odraslih, starih 18 let in več, z vrsto 2 sladkorna bolezen kot dodatek k prehrani in vadbi za izboljšanje glycaemic nadzor:pri bolnikih, ki ni ustrezno nadzorovana na njihovo maksimalno dopustne koncentracije metforminom alonein bolnikov na njihovo maksimalno dopustne koncentracije metforminom skupaj z drugimi glukoze znižanje medicini, vključno z insulina, ko te ne zagotavljajo ustrezne glycaemic nadzor. pri bolnikih, ki se že zdravijo z kombinacijo canagliflozin in metforminom kot ločene tabletsfor študijski rezultati glede kombinacija terapij, vplivi na glycaemic nadzor in srčno-žilne dogodke, in populacije, ki je študiral glej poglavji 4. 4, 4. 5 in 5.

Evropska unija - slovenščina - EMA (European Medicines Agency)

cheplapharm arzneimittel gmbh - pioglitazone, glimepiride - diabetes mellitus, tip 2 - zdravila, ki se uporabljajo pri diabetesu - tandemact je indicirano za zdravljenje bolnikov s sladkorno boleznijo tipa 2, ki kažejo nestrpnosti v metforminom ali za katere je kontraindiciran metformin in ki se že zdravijo s kombinacijo pioglitazone in glimepiride.

Evropska unija - slovenščina - EMA (European Medicines Agency)

novo nordisk a/s - insulin degludec, liraglutide - diabetes mellitus, tip 2 - zdravila, ki se uporabljajo pri diabetesu - xultophy je indicirano za zdravljenje odraslih s sladkorno boleznijo tipa 2 za izboljšanje nadzora glycaemic v kombinaciji z ustni-znižanje glukoze zdravil, ko ti sam ali v kombinaciji z agonist receptorjev za glp-1 ali bazalni insulin ne zagotavljajo ustrezno glycaemic nadzor.

Evropska unija - slovenščina - EMA (European Medicines Agency)

actavis group ptc ehf   - pioglitazon hidroklorid - diabetes mellitus, tip 2 - zdravila, ki se uporabljajo pri diabetesu - pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described below:as monotherapyin adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance. as dual oral therapy in combination withmetformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin. a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea. as triple oral therapy in combination withmetformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy. pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance (see section 4. po začetku terapije z pioglitazone, bolnike je treba pregledati in po 3 do 6 mesecev, da oceni ustreznost odziva na zdravljenje (e. zmanjšanje hba1c). pri bolnikih, ki ne kažejo ustrezen odgovor, pioglitazone, je treba prekiniti,. v luči možnih tveganj z dolgotrajna terapija, predpisovalce morajo potrditi na kasnejše redne preglede, da je korist pioglitazone je ohranjena (glej poglavje 4.

Evropska unija - slovenščina - EMA (European Medicines Agency)

astrazeneca ab - saxagliptin - diabetes mellitus, tip 2 - zdravila, ki se uporabljajo pri diabetesu - add-on combination therapyonglyza is indicated in adult patients aged 18 years and older with type-2 diabetes mellitus to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy:in combination with metformin, when metformin alone, with diet and exercise, does not provide adequate glycaemic control;in combination with a sulphonylurea, when the sulphonylurea alone, with diet and exercise, does not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate;in combination with a thiazolidinedione, when the thiazolidinedione alone with diet and exercise, does not provide adequate glycaemic control in patients for whom use of a thiazolidinedione is considered appropriate;as triple oral therapy:in combination with metformin plus a sulphonylurea when this regimen alone, with diet and exercise, does not provide adequate glycaemic control;as combination therapy with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

Evropska unija - slovenščina - EMA (European Medicines Agency)

sanofi winthrop industrie - insulin glargine, lixisenatide - diabetes mellitus, tip 2 - zdravila, ki se uporabljajo pri diabetesu - suliqua is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to metformin with or without sglt-2 inhibitors.

Evropska unija - slovenščina - EMA (European Medicines Agency)

boehringer ingelheim - empagliflozin, metformin - diabetes mellitus, tip 2 - zdravila, ki se uporabljajo pri diabetesu - synjardy je navedeno pri odraslih, starih 18 let in več, z vrsto 2 sladkorna bolezen kot dodatek k prehrani in vadbi za izboljšanje glycaemic nadzor:pri bolnikih, neustrezno nadzorovano na njihovo maksimalno dopustne odmerek metforminom sam;pri bolnikih, neustrezno nadzorovana z metforminom v kombinaciji z drugimi glukoze-znižanje zdravil, vključno z insulina;pri bolnikih, ki se že zdravijo z kombinacijo empagliflozin in metforminom kot ločene tablete.

Evropska unija - slovenščina - EMA (European Medicines Agency)

novartis europharm ltd. - nateglinid - diabetes mellitus, tip 2 - zdravila, ki se uporabljajo pri diabetesu - nateglinid je indiciran za kombinirano terapijo z metforminom pri bolnikih z diabetesom tipa 2, ki so bili neustrezno nadzorovani kljub največjemu dovoljenemu odmerku samo metformina.

Evropska unija - slovenščina - EMA (European Medicines Agency)

novo nordisk a/s - insulin degludec - sladkorna bolezen - zdravila, ki se uporabljajo pri diabetesu - zdravljenje diabetesa mellitusa pri odraslih.